Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®
Alvotech announced that the FDA has accepted for review its Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio. AVT16 is developed for intravenous administration and is part of a partnership with Teva Pharmaceutical, which holds commercialization rights.
Key figures
- Drug Name
- AVT16
- Phase Of Trial
- BLA submission
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.